By Professor Ric Day

Journal articles

Day RO; Liauw WS; Tozer L; McElduff P; Beckett RJ; Williams K, 2010, 'A double-blind, placebo-controlled study of the short term effects of a spring water supplemented with magnesium bicarbonate on acid/base balance, bone metabolism and cardiovascular risk factors in postmenpausal women', BMC Research Notes, 3, pp. 1 - 8

Indraratna P; Stocker SL; Williams KM; Graham GG; Jones G; Day RO, 2010, 'A proposal for identifying the low renal uric acid clearance phenotype', Arthritis Research and Therapy, 12, pp. 149 - 151

Wallace H; Graham GG; Williams K; Day RO, 2010, 'A risk-benefit assessment of paracetamol (acetaminophen) combined with caffeine', Pain Medicine, 11, pp. 951 - 965

Westbrook JI; Woods A; Rob MI; Dunsmuir WTM; Day RO, 2010, 'Association of interruptions with an increased risk and severity of medication administration errors', Archives of Internal Medicine, 170, pp. 683 - 690, http://dx.doi.org/10.1001/archinternmed.2010.65

Magrabi F; Li S; Day RO; Coiera E, 2010, 'Errors and electronic prescribing: A controlled laboratory study to examine task complexity and interruption effects', American Medical Informatics Association Annual Symposium Proceedings, 17, pp. 575 - 583

Graham GG; Day RO; Graudins A; Mohamudally A, 2010, 'FDA proposals to limit the hepatoxicity of paracetamol (acetaminophen). Are they resonable?', Inflammopharmacology, 18, pp. 47 - 55

Stocker S; Franklin M; Anderson JM; Pillans PI; Williams K; McLachlan AJ; Day RO; taylor P, 2010, 'Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry', Journal of Chromatography, 878, pp. 2363 - 2368

Williams CM; Latimer J; Maher C; McLachlan AJ; Cooper C; Hancock M; Day RO; McAuley J; Lin C, 2010, 'PACE-the first placebo controlled trail of paracetamol for acute low back pain:design of a randomised controlled trial', BMC Musculoskeletal Disorders, 11, pp. 1 - 11, http://www.biomedcentral.com/content/pdf/1471-2474-11-169.pdf

Abdul M; Jiang XM; Williams KM; Day RO; Roufogalis B; Liauw WS; Xu H; Matthias A; Lehmann RP; McLachlan AJ, 2010, 'Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects', British Journal of Clinical Pharmacology, 69, pp. 508 - 515

Standfield L; Norris S; Elliott L; Riordan J; Hall S; Day RO; Nash P; Thirunavukkarasu K; Robertson J; Palmer T, 2010, 'Relationship between rheumatoid arthritis disease severity, health related utility and resource use in Australian rheumatoid arthritis patients', Clinical Therapeutics, 32, pp. 1329 - 1342

Day RO, 2009, 'Adherence to urate-lowering therapy', Southern Medical Journal, 102, pp. 114 - 115

Osborn M; Day RO; Westbrook JI, 2009, 'Are specialist physicians missing out on the e-Health boat?', Internal Medicine Journal, 39, pp. 655 - 661

Hancock M; Maher C; Latimer J; Mclachlan AJ; Day RO; Davies R, 2009, 'Can predictors of response to NSAIDs Be identified in patients with acute low back pain?', Clinical Journal of Pain, 25, pp. 659 - 665

Osborn M; Day RO; Komesaroff P; Mant A, 2009, 'Do ethical guidelines make a difference to decision-making?', Internal Medicine Journal, 39, pp. 800 - 805

Reckmann M; Westbrook JI; Koh Y; Lo CM; Day RO, 2009, 'Does Computerized Provider Order Entry Reduce Prescribing Errors for Hospital Inpatients? A Systematic Review', American Medical Informatics Association Annual Symposium Proceedings, 16, pp. 613 - 623

Indraratna P; Williams KM; Graham GG; Day RO, 2009, 'Hyperuricemia, Cardiovascular Disease and the Metabolic Syndrome', The Journal of Rheumatology, 36, pp. 2842 - 2843

Day RO, 2009, 'India: Emerging centre of drug develpment', Journal of Pharmacy Practice and Research, 39, pp. 262 - 263

Lee P; Greenfield JR; Day RO; Ho K, 2009, 'Weight maintenance in hospitalized geriatric patients treated with beta-blockers', Journal of the American Geriatrics Society, 57, pp. 1125 - 1126

Day RO; Fransen M; Zochling J; March L, 2008, 'Osteoarthritis: NSAIDs, paracetamol or other treatment approaches?', Medicine Today, 9, pp. 71 - 74

Lu CY; Macneill P; Williams K; Day R, 2008, 'Access to high cost medicines in Australia: Ethical perspectives', Australia and New Zealand Health Policy, 5, http://dx.doi.org/10.1186/1743-8462-5-4

Lee M; Graham GG; Williams KM; Day RO, 2008, 'A benefit-risk assessment of benzbromarone in the treatment of gout - was its withdrawal from the market in the best interest of patients?', Drug Safety, 31, pp. 643 - 665

Lu CY; Williams KM; Day RO, 2008, 'Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia', International Journal of Rheumatology, 11, pp. 11 - 14

Xu H; Liauw WS; Murray M; Day RO; Mclachlan AJ, 2008, 'Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide', British Journal of Pharmacology, 153, pp. 1579 - 1586, http://dx.doi.org/10.1038/sj.bjp.0707685

Magrabi F; Westbrook JI; Kidd MR; Day RO; Coiera E, 2008, 'Long-term patterns of online evidence retrieval use in general practice: A 12-month study', Journal of Medical Internet Research, 10

McLachlan AJ; Day RO; Williams KM; Graham GG, 2008, 'Maximising gout therapy', Australian Journal of Pharmacy, 89, pp. 86 - 88

Chung Y; Stocker S; Graham GG; Day RO, 2008, 'Optimizing therapy with allopurinol: Factors limiting hypouricemic efficacy', American Journal of the Medical Sciences, 335, pp. 219 - 226

Abdul M; Jiang XM; Day RO; Roufogalis B; Liauw WS; Xu H; Mclachlan AJ, 2008, 'Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects', British Journal of Pharmacology, 154, pp. 1691 - 1700

Stocker S; Williams KM; Mclachlan AJ; Graham GG; Day RO, 2008, 'Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects', Clinical Pharmacokinetics, 47, pp. 111 - 118

Chung YW; Lu CY; Graham GG; Mant A; Day RO, 2008, 'Utilization of allopurinol in the Australian community', Internal Medicine Journal, 38, pp. 388 - 395

Kaye K; Lu C; Day R, 2007, 'Can we deny patients expensive drugs? [2]', Australian Prescriber, 30, pp. 60

Graham GG; Day RO, 2007, 'Expert comment [6]', Australian Prescriber, 30, pp. 61 - 62

Graham GG; Day RO, 2007, 'Paracetamol comment', AUSTRALIAN PRESCRIBER, 30, pp. 61 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000434589000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Murnion BP; Granot R; Day RO, 2007, 'Utility of urine drug screening: A clinical audit', EMA Emergency Medicine Australasia, 19, pp. 246 - 252, http://dx.doi.org/10.1111/j.1742-6723.2007.00922.x

Lu CY; Williams KM; Day RO, 2007, 'The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines', Australia and New Zealand Health Policy, 4, http://dx.doi.org/10.1186/1743-8462-4-2

Day RO; Graham G; Williams K, 2007, 'Fenofibratewarfarin interaction [1]', Australian Prescriber, 30, pp. 32, http://dx.doi.org/10.18773/austprescr.2007.014

Day R; Lu CY; Pearce G; Grainger D, 2007, 'Pharmaceutical benefits scheme: Rapid change and impetus towards achieving QUM', Journal of Pharmacy Practice and Research, 37, pp. 4 - 6, http://dx.doi.org/10.1002/j.2055-2335.2007.tb00644.x

Granot R; Day RO; Cohen ML; Murnion B; Garrick R, 2007, 'Targeted pharmacotherapy of evoked phenomena in neuropathic pain: A review of the current evidence', Pain Medicine, 8, pp. 48 - 64, http://dx.doi.org/10.1111/j.1526-4637.2007.00156.x

Granot R; Day RO; Cohen ML; Murnion B; Garrick R, 2007, '639: Targeted pharmacotherapy of evoked phenomena in neuropathic pain', Journal of Clinical Neuroscience, 14, pp. 1031 - 1031, http://dx.doi.org/10.1016/j.jocn.2007.02.070

Hancock M; Maher CG; Latimer J; Mclachlan AJ; Cooper C; Day RO; Spindler M; McAuley J, 2007, 'Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial', Lancet, 370, pp. 1638 - 1643

Day RO; Graham GG; Hicks M; Mclachlan AJ; Stocker S; Williams KM, 2007, 'Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol', Clinical Pharmacokinetics, 46, pp. 623 - 644

Kelman CW; Pearson S; Day RO; D Arcy C; Holman JW; Kliewer E; Henry D, 2007, 'Evaluating medicines: let`s use all the evidence', Medical Journal of Australia, 186, pp. 249 - 252

Lu CY; Williams KM; Day RO, 2007, 'Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?', Internal Medicine Journal, 37, pp. 601 - 606, http://dx.doi.org/10.1111/j.1445-5994.2007.01396.x

Mikhail S; Zwar NA; Vagholkar S; Dennis SM; Day RO, 2007, 'Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma', Medical Journal of Australia, 187, pp. 160 - 163

Day RO; Williams KM, 2007, 'Open-label extension studies - Do they provide meaningful information on the safety of new drugs?', Drug Safety, 30, pp. 93 - 105

Pearson S; Ringland C; Kelman CW; Mant A; Lowinger J; Stark H; Nichol G; Day RO; Henry DA, 2007, 'Patterns of analgesic and anti-inflammatory medicine use by Australian veterans', Internal Medicine Journal, 37, pp. 798 - 805

Tan E; Day RO; Brien JE, 2007, 'Prioritising drug and therapeutics committee (DTC) decisions: a national survey', Pharmacy World and Science, 29, pp. 90 - 96

Miners JO; Day RO, 2007, 'Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes', British Journal of Clinical Pharmacology, 63, pp. 380 - 381

Lu C; Ritchie JE; Williams KM; Day RO, 2007, 'The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia', Australia and New Zealand Health Policy, 4

McNeill PM; Kerridge IH; Arciuli C; Henry DA; Macdonald GJ; Day RO; Hill SR, 2006, 'Gifts, Drug Samples, and other Items Given to Medical Specialists by Pharmaceutical Companies', Journal of Bioethical Inquiry, 3, pp. 139 - 148, http://dx.doi.org/10.1007/s11673-006-9019-0

Reicin A; Shapiro D, 2006, 'Response to expression of concern regarding VIGOR study.', N Engl J Med, 354, pp. 1196 - 1199, https://www.ncbi.nlm.nih.gov/pubmed/16544387

Back to profile page